Core Viewpoint - The core strategic challenge for Giant Biological Management in 2026 is to balance brand strength and profit margin protection [5] Financial Performance - In 2025, Giant Biological reported revenue of 5.519 billion yuan, a year-on-year decrease of 0.4%, and a net profit attributable to shareholders of 1.915 billion yuan, down 7.2% [2] - Adjusted net profit for 2025 was 1.96 billion yuan, reflecting an 8.9% decline, with a gross margin of approximately 80.3%, down 1.8 percentage points [2] - This marks the first instance of revenue and net profit decline since the company's listing in 2022, contrasting with double-digit growth from 2022 to 2024 [2] Brand and Market Dynamics - The core brand, Cofu Mei, generated revenue of 4.47 billion yuan in 2025, accounting for over 80% of total revenue, but experienced a 1.6% decline, significantly impacting overall performance [4] - The decline in Cofu Mei's revenue is attributed to external shocks and intensified price competition within the industry [4] - The brand's online GMV during the 2025 Double Eleven shopping festival fell by approximately 30%, with a 20% decline on Tmall and a 50% drop on Douyin, primarily due to a strategic decision to avoid price wars [4] Cost Structure - In 2025, sales expenses increased by 2.4% due to ongoing investments in brand building, while management expenses rose by 11.9% due to personnel expansion and digital upgrades [3] - Research and development expenses decreased by 16.6%, reflecting a shift as some projects moved into the results conversion phase [3] Competitive Landscape - The market for collagen products is becoming increasingly competitive, with new entrants from traditional medical and pharmaceutical companies [6] - The brand's credibility was challenged when a beauty influencer questioned the collagen content in Cofu Mei's products, leading to a significant impact on brand reputation and sales [6] Future Strategies - Giant Biological plans to enhance innovation in raw material development and accelerate the approval of Class III medical devices [7] - The company aims to create replicable blockbuster products and launch new brands in emerging business sectors to drive revenue growth [7]
成分疑云笼罩，巨子生物业绩增长急踩刹车